ROLPA — Full immunisation has been guaranteed in forty-eight districts of the country. This information was shared at a programme organised in district headquarters Libang, on Monday, to declare Rolpa district as achieving this status.
Minister for Social Development of Province 5 government, Sudarshan Baral, declared that Rolpa had joined the league of districts where full immunisation has been guaranteed.
He highlighted the importance of immunisation for improving the health condition of citizens. The provincial government minister said only healthy citizens could contribute meaningfully to country’s development.
Rolpa was declared achieving the status of ‘full immunisation’ as all children below the age of 15 months in the district have been administered 11 various immunisation shots as per the immunisation schedule.
With this, Rolpa has achieved 95 per cent immunisation, Chief of District Public Health Office, Dr Sushil Acharya, said on the occasion.
Representative of the Department of Health Services, Basanta Shrestha, said on the occasion that all 77 districts of the country would be declared ‘district with full immunisation’ within 2018.
Meanwhile, Baglung has also been declared as achieving the status of ‘district with full immunisation’. This announcement was made at a programme organised in the district headquarters on Monday.
On the occasion, Minister for Social Development of Gandaki Province, Naradevi Pun Magar, provincial assembly members, people’s representatives of local bodies, political party chiefs of the district, among other officials signed on a pledge to make Baglung continue with the status.
Similarly, Lahan Municipality in Siraha district has been declared ‘municipality achieving full immunisation’ amidst a programme in Lahan on Monday.Follow @gorkhapost
Diabetes drug might ease heart failure risk
A new research has showed that the diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure.
According to the findings were published in the New England Journal of Medicine to coincide with their presentation at the annual meeting of the American Heart Association in Chicago, Type 2 diabetics who took Farxiga saw their odds of hospitalization for heart failure drop by 27 percent compared to those who took a placebo.
Farxiga is a type of drug called a SGLT2 inhibitor. The compound is called dapagliflozin.
The study included more than 17,000 type 2 diabetes patients aged 40 and older. Nearly 7,000 had heart disease and more than 10,000 had numerous risk factors for heart disease, Wiviott’s group said.
Patients were randomly assigned to take a dummy placebo pill or 10 milligrams of Farxiga each day.
“When it comes to helping our patients control and manage blood glucose, the ‘how’ appears to be as important [as] the ‘how much,” said study author Dr Stephen Wiviott, a cardiovascular medicine specialist at Brigham and Women’s Hospital in Boston.
“When choosing a therapy, trial results like these can help us make an informed decision about what treatments are not only safe and effective for lowering blood glucose but can also reduce risk of heart and kidney complications,” Wiviott said in a hospital news release.
Taking the drug did not reduce the risk of heart attack, stroke and cardiovascular-related death, the research team noted. However, patients who took the drug did see healthy declines in their blood sugar levels, plus an added bonus: a 27 percent decrease in their risk of hospitalization for heart failure.
Their risk of kidney failure and death from kidney failure also fell, researchers noted.
Two other recent studies of this class of drugs show that they “robustly and consistently improve heart and kidney outcomes in a broad population of patients with diabetes,” Wiviott noted.
With Inputs from HealthDayFollow @gorkhapost